The relationship between vitamin K2 and erectile function is not a direct one, and any article claiming otherwise is ahead of the data. What connects them is the artery wall. Erection is a haemodynamic event that depends on arteries capable of dilating quickly and substantially, and one of the processes that quietly removes that capacity over decades is vascular calcification — the deposition of mineral in the arterial media and intima. Vitamin K2 sits directly upstream of the body's principal defence against that process. Understanding what the evidence supports, and where it stops, is more useful to men over forty than another list of supplement claims.
Erectile function is an early readout on the arterial tree
The penile arteries are small. Their diameter is roughly a third to a half that of the coronary arteries, which means a given degree of arterial wall disease produces a proportionally larger reduction in flow reserve there first. This is the anatomical basis for what urologists and cardiologists have described for two decades: erectile difficulty of vascular origin frequently precedes a coronary event by several years.
The imaging evidence is direct. In a controlled study of 70 men with vascular erectile dysfunction confirmed by penile Doppler, compared with 73 men with no history of coronary disease, the men with erectile dysfunction had an odds ratio of 3.52 for a coronary artery calcium score above the 75th percentile [1]. They also showed impaired flow-mediated dilation of the brachial artery and higher high-sensitivity C-reactive protein. Larger contemporary cohorts have reproduced the association and shown that it tracks with severity — men with more severe erectile dysfunction carry higher calcium scores.
The important word in that finding is calcium. The measurement used was not plaque volume or stenosis; it was mineral. Calcification is not simply a marker of advanced atherosclerosis. It is an active, regulated process, and it independently degrades the property erections depend on most: the ability of an artery to change its diameter on demand. A calcified vessel is a stiff vessel, and a stiff vessel dilates poorly regardless of how much nitric oxide is signalling it to relax.
Matrix Gla protein: the vitamin K-dependent brake
Arterial calcification is not a passive chemical inevitability. Blood is supersaturated with calcium and phosphate; without active inhibition, soft tissue would mineralise continuously. The dominant local inhibitor in the vessel wall is matrix Gla protein (MGP), a small protein secreted by vascular smooth muscle cells and chondrocytes [2].
MGP only works after post-translational modification. It must be carboxylated — a reaction that converts specific glutamate residues into gamma-carboxyglutamate (Gla) residues, giving the protein the calcium-binding capacity it needs to sequester mineral and block crystal growth. That carboxylation reaction requires vitamin K as an essential cofactor. Without adequate vitamin K, MGP is synthesised but remains in its uncarboxylated, functionally inert form [2].
This gives clinicians a measurable biomarker. Plasma dephosphorylated-uncarboxylated MGP (dp-ucMGP) reflects the pool of non-functional protein and rises when vitamin K status is inadequate. In a cohort of haemodialysis patients, dp-ucMGP concentration was both predictive of vitamin K status and correlated with the extent of vascular calcification [3]. Similar relationships have been reported in acute coronary syndrome and chronic kidney disease populations. The mechanistic chain — low vitamin K, undercarboxylated MGP, less calcification inhibition, more arterial mineral — is one of the better-characterised nutrient-to-vascular-pathology pathways in the literature.
Menaquinone (vitamin K2) is more relevant here than phylloquinone (vitamin K1). K1 is preferentially taken up by the liver for coagulation factor synthesis; the longer-chain menaquinones, particularly MK-7, have a substantially longer circulating half-life and reach extrahepatic tissue, including the vessel wall, in meaningful quantity.
What vitamin K2 and erectile function research does — and does not — establish
Here the evidence must be reported carefully. There is no randomised trial of vitamin K2 with an erectile endpoint. Not one. Anyone citing a direct K2-to-erection trial is citing something that does not exist.
What does exist is outcome data on the intermediate pathway. In the Rotterdam Study, 4,807 participants with dietary data and no prior myocardial infarction were followed for roughly a decade. Men and women in the highest tertile of dietary menaquinone intake had a relative risk of coronary heart disease mortality of 0.43 (95% CI 0.24–0.77) compared with the lowest tertile, and an odds ratio for severe aortic calcification of 0.48 (95% CI 0.32–0.71). Phylloquinone intake showed no relationship with any outcome [4]. That contrast between K1 and K2 is what makes the finding mechanistically credible rather than merely a marker of a healthier diet.
Interventional data followed. In a three-year double-blind randomised trial, 244 healthy postmenopausal women received 180 µg/day of MK-7 or placebo. The MK-7 group showed significant improvement in carotid stiffness measured by echotracking and a reduction in aortic pulse wave velocity, the standard index of regional arterial stiffness [5]. A 2023 systematic review and meta-analysis pooling 14 randomised controlled trials and 1,533 participants found that vitamin K supplementation significantly slowed coronary artery calcification progression (mean difference −17.37, 95% CI −34.18 to −0.56) and substantially reduced dp-ucMGP, with no excess of adverse events [6].
So the honest summary is this: vitamin K2 has randomised evidence for reducing arterial stiffness and slowing calcification progression, in populations that were mostly postmenopausal women or dialysis patients rather than middle-aged men, and no evidence at all for a direct erectile benefit. The inference from a stiffer, more calcified arterial tree to poorer erectile haemodynamics is biologically sound and supported by the imaging data in section one, but it remains an inference. Clinical studies suggest a vascular benefit; they do not demonstrate a sexual one.
Why K2 is usually paired with vitamin D3
Vitamin D3 and K2 are frequently formulated together, and the rationale is physiological rather than commercial. Vitamin D increases intestinal calcium absorption and upregulates the expression of several Gla proteins, including MGP and osteocalcin. That raises the demand for vitamin K-dependent carboxylation. If vitamin D status improves while vitamin K remains inadequate, the theoretical result is more circulating calcium and more uncarboxylated MGP available to direct it — the combination least desirable in the vessel wall. Pairing the two is intended to keep the carboxylation capacity matched to the calcium load.
Vitamin D has its own, more equivocal, relationship with erectile function. A systematic review and meta-analysis of eight observational studies totalling 4,055 men found no overall difference in 25-hydroxyvitamin D between men with and without erectile dysfunction. However, men who were frankly deficient (below 20 ng/mL) had significantly worse erectile function scores than controls, an association that persisted after excluding men with hypogonadism, and men with severe erectile dysfunction had lower vitamin D levels than those with mild disease [7]. The reasonable reading is that correcting deficiency may matter and supplementing an already-sufficient man probably does not.
Where this fits in clinical practice
Calcification is a decades-long process, which sets realistic expectations in both directions. A K2 strategy is a slow structural intervention, not something that changes erectile quality over weeks. Its plausible value is in the trajectory: preserving arterial compliance in a man in his forties or fifties so that the vascular substrate remains responsive later.
Three cautions apply. First, vitamin K antagonist anticoagulants — warfarin and related agents — work by blocking exactly the carboxylation reaction described above. Any vitamin K intake is a direct pharmacological interaction, and men on warfarin should change nothing without their prescriber's involvement. Second, existing calcification does not reverse; the randomised data show slowed progression, not regression. Third, and most practically, calcification is one contributor among several. Endothelial nitric oxide production, glycaemic control, testosterone status, sleep, and medication effects frequently matter more in any individual man, and a man with new erectile symptoms needs an evaluation rather than a supplement.
Conclusion
Vitamin K2 occupies a well-defined position in vascular biology. It is the cofactor without which matrix Gla protein cannot restrain mineral deposition in the artery wall, and the consequences of inadequate status are measurable as elevated dp-ucMGP, greater aortic calcification, and stiffer arteries. Randomised trials show that supplementation slows calcification progression and improves arterial stiffness. Because erectile function is an early and sensitive readout of arterial compliance — men with vascular erectile dysfunction carry roughly three and a half times the odds of a high coronary calcium score — maintaining that compliance is a rational long-term goal. What the evidence does not support is treating K2 as an erectile therapy. Some men may benefit from correcting a genuine deficiency as part of broader vascular care; where erectile symptoms are already present, clinical management typically pairs that vascular work with a prescribed PDE5 inhibitor that directly amplifies the nitric oxide signalling in cavernosal tissue. For related reading see our review of vitamin D deficiency and erectile dysfunction, our overview of arterial stiffness and erectile dysfunction, and the rest of our clinical library.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com, including the daily chewable formulation EPIQ Chews, which combines tadalafil and vardenafil with vitamin D3 and K2.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Chiurlia E, D'Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. Journal of the American College of Cardiology. 2005;46(8):1503-1506. doi:10.1016/j.jacc.2005.06.068
- Schurgers LJ, Cranenburg ECM, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thrombosis and Haemostasis. 2008;100(4):593-603. doi:10.1160/TH08-02-0087
- Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrology. 2014;15:145. doi:10.1186/1471-2369-15-145
- Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of Nutrition. 2004;134(11):3100-3105. doi:10.1093/jn/134.11.3100
- Knapen MHJ, Braam LAJLM, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015;113(5):1135-1144. doi:10.1160/TH14-08-0675
- Li T, Wang Y, Tu WP. Vitamin K supplementation and vascular calcification: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Nutrition. 2023;10:1115069. doi:10.3389/fnut.2023.1115069
- Crafa A, Cannarella R, Condorelli RA, La Vignera S, Calogero AE. Is there an association between vitamin D deficiency and erectile dysfunction? A systematic review and meta-analysis. Nutrients. 2020;12(5):1411. doi:10.3390/nu12051411
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.